Pennathur A. Gibson M.K. Jobe B.A.

Luketich JD oesophageal carcinoma.

Lancet. 381: 400-412

Esophageal cancer: epidemiology, pathogenesis and prevention.

Nat Clin Pract Gastroenterol Hepatol. 5: 517-526Halperin E.C.P.C. Brady L.W.

Perez and Brady’s Principles and Practice of Radiation Oncology.

Lippincott Williams & Wilkins, Philadelphia, PA: 1137Shields T.W.L.J. Reed C.E. Feins R.H.

General Thoracic Surgery.

Lippincott Williams & Wilkins, Philadelphia, PA: 2047Zeng H. Zheng R. Zhang S. et al.

Esophageal cancer statistics in China, 2011: estimates based on 177 cancer registries.

Thorac Cancer. 7: 232-237

Benipal B incidence of esophageal cancer in the United States from 2001-2015: a United States cancer statistics analysis of 50 states.

Cureus. 10: e3709Hongo M. Nagasaki Y. Shoji T.

Epidemiology of esophageal cancer: orient to Occident. Effects of chronology, geography and ethnicity.

J Gastroenterol Hepatol. 24: 729-735Hur C. Miller M. Kong C.Y. et al.

Trends in esophageal adenocarcinoma incidence and mortality.

Cancer. 119: 1149-1158Watanabe M. Otake R. Kozuki R. et al.

Recent progress in multidisciplinary treatment for patients with esophageal cancer.

Surg Today. 50: 12-20Cools-Lartigue J. Ferri L.

Should multidisciplinary treatment differ for esophageal adenocarcinoma versus esophageal squamous cell cancer?.

Ann Surg Oncol. 26: 1014-1027Villaflor V.M. Allaix M.E. Minsky B. Herbella F.A.

Patti MG Multidisciplinary approach for patients with esophageal cancer.

World J Gastroenterol. 18: 6737-6746Staff N For Esophageal Cancer

Immunotherapy likely to play larger role.

National Cancer Institute, Bethesda, MDDavidson B.L. McCray Jr., P.B.

Current prospects for RNA interference-based therapies.

Nat Rev Genet. 12: 329-340Leung R.K. Whittaker P.A.

RNA interference: from gene silencing to gene-specific therapeutics.

Pharmacol Ther. 107: 222-239Moore C.B. Guthrie E.H. Huang M.T.

Taxman DJ Short hairpin RNA (shRNA): design, delivery, and assessment of gene knockdown.

Methods Mol Biol. 629: 141-158Yu X. Li W. Xia Z. et al.

Targeting MCL-1 sensitizes human esophageal squamous cell carcinoma cells to cisplatin-induced apoptosis.

BMC Cancer. 17: 449Jing S.W. Wang Y.D. Chen L.Q. et al.

Hypoxia suppresses E-cadherin and enhances matrix metalloproteinase-2 expression favoring esophageal carcinoma migration and invasion via hypoxia inducible factor-1 alpha activation.

Dis Esophagus. 26: 75-83Wang L. Jin J.Q. Zhou Y. et al.

Gli is activated and promotes epithelial-mesenchymal transition in human esophageal adenocarcinoma.

Oncotarget. 9: 853-865Ito T. Sato F. Kan T. et al.

Polo-like kinase 1 regulates cell proliferation and is targeted by miR-593∗ in esophageal cancer.

Int J Cancer. 129: 2134-2146Kim J. Yao F. Xiao Z. Sun Y. Ma L.

MicroRNAs and metastasis: small RNAs play big roles.

Cancer Metastasis Rev. 37: 5-15Shi X. Dou Y. Zhou K. et al.

Targeting the Bcl-2 family and P-glycoprotein reverses paclitaxel resistance in human esophageal carcinoma cell line.

Biomed Pharmacother. 90: 897-905Bonde P. Gao D. Chen L. et al.

Duodenal reflux leads to down regulation of DNA mismatch repair pathway in an animal model of esophageal cancer.

Ann Thorac Surg. 83: 433-440Kelly R.J. Ansari A.M. Miyashita T. et al.

Targeting the Hedgehog pathway using itraconazole to prevent progression of barrett's esophagus to invasive esophageal adenocarcinoma.

Ann Surg. 273: e206-e213Wang D.H. Clemons N.J. Miyashita T. et al.

Aberrant epithelial-mesenchymal Hedgehog signaling characterizes Barrett's metaplasia.

Gastroenterology. 138: 1810-1822Bonde P. Gao D. Chen L. et al.

Selective decrease in the DNA base excision repair pathway in squamous cell cancer of the esophagus.

J Thorac Cardiovasc Surg. 133: 74-81Bonde P. Sui G. Dhara S. et al.

Cytogenetic characterization and gene expression profiling in the rat reflux-induced esophageal tumor model.

J Thorac Cardiovasc Surg. 133: 763-769Mori Y. Okumura T. Tsunoda S. Sakai Y. Shimada Y.

Gli-1 expression is associated with lymph node metastasis and tumor progression in esophageal squamous cell carcinoma.

Oncology. 70: 378-389Hui W. Kuisheng C. Hongxin Z. et al.

Influence of smoothened siRNA on human esophageal cancer cell line EC9706 proliferation and apoptosis.

Pak J Pharm Sci. 27: 1661-1667Ohbu M. Saegusa M. Kobayashi N. et al.

Expression of bcl-2 protein in esophageal squamous cell carcinomas and its association with lymph node metastasis.

Cancer. 79: 1287-1293Takayama T. Nagao M. Sawada H. et al.

Bcl-X expression in esophageal squamous cell carcinoma: association with tumor progression and prognosis.

J Surg Oncol. 78: 116-123Tong Z. Mejia A. Veeranki O. et al.

Targeting CDK9 and MCL-1 by a new CDK9/p-TEFb inhibitor with and without 5-fluorouracil in esophageal adenocarcinoma.

Ther Adv Med Oncol. 11 ()Jing S.W. Wang Y.D. Kuroda M. et al.

HIF-1alpha contributes to hypoxia-induced invasion and metastasis of esophageal carcinoma via inhibiting E-cadherin and promoting MMP-2 expression.

Acta Med Okayama. 66: 399-407Yang C. Zheng X. Ye K. et al.

miR-135a inhibits the invasion and migration of esophageal cancer stem cells through the Hedgehog signaling pathway by targeting Smo.

Mol Ther Nucleic Acids. 19: 841-852Xie Y.E. Tang E.J. Zhang D.R.

Ren BX Down-regulation of Bcl-XL by RNA interference suppresses cell growth and induces apoptosis in human esophageal cancer cells.

World J Gastroenterol. 12: 7472-7477Wang X.X. Liu R. Jin S.Q. Fan F.Y.

Zhan QM Overexpression of Aurora-A kinase promotes tumor cell proliferation and inhibits apoptosis in esophageal squamous cell carcinoma cell line.

Cell Res. 16: 356-366Zhu H. Feng Y. Zhang J. et al.

Inhibition of hypoxia inducible factor 1alpha expression suppresses the progression of esophageal squamous cell carcinoma.

Cancer Biol Ther. 11: 981-987Tang N.N. Zhu H. Zhang H.J. et al.

HIF-1alpha induces VE-cadherin expression and modulates vasculogenic mimicry in esophageal carcinoma cells.

World J Gastroenterol. 20: 17894-17904Hu X. Lin J. Jiang M. et al.

HIF-1alpha promotes the metastasis of esophageal squamous cell carcinoma by targeting SP1.

J Cancer. 11: 229-240Liao H.Y. Wang G.P. Gu L.J. et al.

HIF-1alpha siRNA and cisplatin in combination suppress tumor growth in a nude mice model of esophageal squamous cell carcinoma.

Asian Pac J Cancer Prev. 13: 473-477Dvorak K. Chavarria M. Payne C.M. et al.

Activation of the interleukin-6/STAT3 antiapoptotic pathway in esophageal cells by bile acids and low pH: relevance to barrett's esophagus.

Clin Cancer Res. 13: 5305-5313Zhang Y. Du X.L. Wang C.J. et al.

Reciprocal activation between PLK1 and Stat3 contributes to survival and proliferation of esophageal cancer cells.

Gastroenterology. 142: 521-530.e523Wang D. Nagle P.W. Wang H.H. et al.

Hedgehog pathway as a potential intervention target in esophageal cancer.

Cancers (Basel). 11: 821Rimkus T.K. Carpenter R.L. Qasem S. Chan M. Lo H.W.

Targeting the sonic Hedgehog signaling pathway: review of smoothened and GLI inhibitors.

Cancers (Basel). 8: 22

Hebrok M Hedgehog signalling in cancer formation and maintenance.

Nat Rev Cancer. 3: 903-911Ma X. Sheng T. Zhang Y. et al.

Hedgehog signaling is activated in subsets of esophageal cancers.

Int J Cancer. 118: 139-148Watkins D.N. Berman D.M. Burkholder S.G. et al.

Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer.

Nature. 422: 313-317Berman D.M. Karhadkar S.S. Maitra A. et al.

Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours.

Nature. 425: 846-851Thayer S.P. di Magliano M.P. Heiser P.W. et al.

Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis.

Nature. 425: 851-856

The basics of epithelial-mesenchymal transition.

J Clin Invest. 119: 1420-1428Wang Y. Ding Q. Yen C.J. et al.

The crosstalk of mTOR/S6K1 and Hedgehog pathways.

Cancer Cell. 21: 374-387Yang Z. Cui Y. Ni W. Kim S. Xuan Y.

Gli1, a potential regulator of esophageal cancer stem cell, is identified as an independent adverse prognostic factor in esophageal squamous cell carcinoma.

J Cancer Res Clin Oncol. 143: 243-254Okereke I.C. Fan Q.L. Pulikal A. Kohtz P.

Xie J Gli1 expression with survival in esophageal adenocarcinoma.

Austin J Cancer Clin Res. 2: 1031

Role of Bcl-2 family proteins in apoptosis: apoptosomes or mitochondria?.

Genes Cells. 3: 697-707Shamas-Din A. Kale J. Leber B. Andrews D.W.

Mechanisms of action of Bcl-2 family proteins.

Cold Spring Harb Perspect Biol. 5: a008714Lomonosova E. Chinnadurai G.

BH3-only proteins in apoptosis and beyond: an overview.

Oncogene. 27: 2-19Sarbia M. Bittinger F. Porschen R. et al.

bcl-2 expression and prognosis in squamous-cell carcinomas of the esophagus.

Int J Cancer. 69: 324-328Hsia J.Y. Chen C.Y. Hsu C.P. et al.

Expression of apoptosis-regulating proteins p53, Bcl-2, and Bax in primary resected esophageal squamous cell carcinoma.

Neoplasma. 48: 483-488

Oxygen sensing, homeostasis, and disease.

N Engl J Med. 365: 537-547

Ratcliffe PJ Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway.

Mol Cel. 30: 393-402Kurokawa T. Miyamoto M. Kato K. et al.

Overexpression of hypoxia-inducible-factor 1alpha(HIF-1alpha) in oesophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage.

Br J Cancer. 89: 1042-1047

Giaccia AJ Hypoxia, gene expression, and metastasis.

Cancer Metastasis Rev. 26: 333-339

Graham CH Hypoxia-driven selection of the metastatic phenotype.

Cancer Metastasis Rev. 26: 319-331Moeller B.J. Richardson R.A.

Dewhirst MW Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment.

Cancer Metastasis Rev. 26: 241-248

Semenza GL hypoxia-inducible factors: master regulators of cancer progression.

Trends Cancer. 2: 758-770

Expression of hypoxia inducible factor 1 alpha and its clinical significance in esophageal carcinoma: a meta-analysis.

Tumour Biol. 39 ()

A epithelial-mesenchymal transition and cell invasion.

Toxicol Res. 26: 245-252Maniotis A.J. Folberg R. Hess A. et al.

Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry.

Am J Pathol. 155: 739-752Hujanen R. Almahmoudi R. Karinen S. et al.

Vasculogenic mimicry: a promising prognosticator in head and neck squamous cell carcinoma and esophageal cancer? A systematic review and meta-analysis.

Cells. 9: 507Zhang J. Zhang G. Hu P. et al.

Vasculogenic mimicry is associated with increased tumor-infiltrating neutrophil and poor outcome in esophageal squamous cell carcinoma.

Onco Targets Ther. 10: 2923-2930

Azizkhan-Clifford J Sp1 and the 'hallmarks of cancer'.

FEBS J. 282: 224-258Ge Q. Xu J.J. Evans D.M. et al.

Leveraging therapeutic potential of multi-targeted siRNA inhibitors.

Future Med Chem. 1: 1671-1681Molyneaux M. Berman B. Xu J. Evans D.M. Lu P.Y.

15580 Effect of TGF-β1/COX-2 small interfering RNA combination product (STP705) on cell viability and tumor growth in a human squamous carcinoma xenograft tumor model in nude mice.

J Am Acad Dermatol. 83: AB156Molyneaux M. Xu J. Evans D.M. Lu P.

Effect on tumor growth by TGF-β1/COX-2 siRNA combination product (STP705) in a human cholangiocarcinoma (HuCCT-1) xenograft tumor model in nude mice.

J Clin Oncol. 37: e14652Kobayashi Y. Tian S. Ui-Tei K.

The siRNA off-target effect is determined by base-pairing stabilities of two different regions with opposite effects.

Genes (Basel). 13: 319Seok H. Lee H. Jang E.S. Chi S.W.

Evaluation and control of miRNA-like off-target repression for RNA interference.

Cell Mol Life Sci. 75: 797-814Kobayashi Y. Miyamoto K. Aida M. Ui-Tei K.

Selection of chemical modifications in the siRNA seed region that repress off-target effect.

Methods Mol Biol. 2282: 17-30Ge Q. Evans D. Xu J.J. Yang H.H. Lu P.Y.

Pulmonary delivery of small interfering RNA for novel therapeutics.

Deliv Tech Biopharmaceuticals. 14: 269-289Bao Q. Ganbold T. Qiburi Q. et al.

AMP functionalized curdlan nanoparticles as a siRNA carrier: synthesis, characterization and targeted delivery via adenosine A2B receptor.

Int J Biol Macromol. 193: 866-873Ganbold T. Han S. Hasi A. Baigude H.

Receptor-mediated delivery of therapeutic RNA by peptide functionalized curdlan nanoparticles.

Int J Biol Macromol. 126: 633-640